Mar 5 |
Dyne Therapeutics GAAP EPS of -$1.09 misses by $0.17
|
Mar 5 |
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
|
Mar 2 |
CEO & President Joshua Brumm Sells 100,000 Shares of Dyne Therapeutics Inc (DYN)
|
Feb 29 |
14 Stocks With Heavy Insider Buying In 2024
|
Feb 21 |
Dyne Therapeutics: An Updated Analysis
|
Feb 15 |
Top 4 Health Care Stocks You May Want To Dump In February
|
Feb 14 |
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
|
Feb 1 |
Dyne Therapeutics to Present at February Investor Conferences
|
Jan 27 |
Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN)
|
Jan 26 |
Dyne Therapeutics jumps amid report of takeover interest
|